Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -10386.54% is 288% below its 5-year average of -2675.03%, near the high end of its 5-year range (-257447.06%–0.00%).
2364.95% below its 12-month average of -421.37%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
OPERATING MARGIN
-10386.54%
OPERATING MARGIN AVG TTM
-421.37%
OPERATING MARGIN AVG 3Y
-8722.56%
OPERATING MARGIN AVG 5Y
-2675.03%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-2364.95%
CURRENT VS 3Y AVG
-19.08%
CURRENT VS 5Y AVG
-288.28%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Inhibrx Biosciences Inc.
Market Cap
$1.37B
Operating Margin
-10386.54%
TTM Avg
-421.37%
3Y Avg
-8722.56%
5Y Avg
-2675.03%
Market Cap
$1.39B
Operating Margin
5.77%
TTM Avg
5.45%
3Y Avg
4.55%
5Y Avg
4.02%
Market Cap
$1.34B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.40B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.40B
Operating Margin
-1130.65%
TTM Avg
-1114.10%
3Y Avg
-1933.52%
5Y Avg
-1289.01%
Market Cap
$1.33B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.42B
Operating Margin
20.42%
TTM Avg
-52.76%
3Y Avg
-545.80%
5Y Avg
-384.16%
Market Cap
$1.42B
Operating Margin
-73.77%
TTM Avg
-87.58%
3Y Avg
-121.21%
5Y Avg
-119.21%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibrx Biosciences Inc. (INBX) | $1.37B | -10386.54% | -421.37% | -8722.56% | -2675.03% |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 5.77% | 5.45% | 4.55% | 4.02% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Omeros Corporation (OMER)vs › | $1.34B | 0.00% | 0.00% | 0.00% | 0.00% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | 0.00% | 0.00% | 0.00% | 0.00% |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | -1130.65% | -1114.10% | -1933.52% | -1289.01% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.33B | 0.00% | 0.00% | 0.00% | 0.00% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 20.42% | -52.76% | -545.80% | -384.16% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | -73.77% | -87.58% | -121.21% | -119.21% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
-91.0%
Operating Margin
-10386.5%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | -2106.85% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | -49928.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | -160898.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | -5403.24% |
| 2023-09-30 | -38510.08% |
| 2023-06-30 | -137796.67% |
| 2023-03-31 | -257447.06% |
| 2022-12-31 | -12956.20% |
| 2022-09-30 | -10792.45% |
| 2022-06-30 | -4865.96% |
| 2022-03-31 | -3172.79% |
| 2021-12-31 | -684.91% |
| 2021-09-30 | -742.54% |
| 2021-06-30 | -2075.58% |
| 2021-03-31 | -2150.41% |
| 2020-12-31 | -616.25% |
| 2020-09-30 | -267.04% |
| 2020-06-30 | -514.91% |
| 2020-03-31 | -2019.61% |
| 2019-12-31 | -5128.46% |
| 2019-09-30 | -1643.20% |
| 2019-06-30 | -1060.10% |
| 2019-03-31 | -51.37% |
| 2018-12-31 | -179.90% |
| 2018-06-30 | -266.92% |
| 2018-03-31 | -355.88% |
| 2017-12-31 | -2807.12% |
